Knowledge base · Peer-reviewed

ScaleWiki.

Peer-reviewed manuscripts on the G-Rex® platform — one citable page per paper, curated so you find the evidence that moves your cell & gene therapy program forward.

487Manuscripts indexed
14Cell types
Live indexContinuously updated

Showing 12 of 530 resources

Publications TIL Cells G-Rex®100M-CS

Publication Date: August 12, 2021

Tumor-infiltrating lymphocyte treatment for anti-PD-1 resistant metastatic lung cancer: a phase I trial

In a phase I trial at two academic centers, autologous tumor-infiltrating lymphocytes combined with nivolumab were feasible and clinically active in 20 patients with metastatic non-small cell lung cancer. TIL were grown from minced tumor fragments in IL-2, then expanded with feeder cells and anti-CD3, and were successfully produced for 95% of patients at a median dose of 95 billion CD3-positive cells. Sixteen patients received cyclophosphamide and fludarabine lymphodepletion, TIL and IL-2; the severe toxicity rate was 12.5%, meeting the safety endpoint. Two complete responses remained ongoing 1.5 years later. T cells recognizing tumor mutations or cancer testis antigens were found in most…

Download Now →

Author: Benjamin C. Creelan, Chao Wang +24 more

Publications CAR T Cells, T-Cells G-Rex®24 Well Plate

Publication Date: August 9, 2021

p16INK4a Regulates Cellular Senescence in PD-1-Expressing Human T Cells

Senescence, marked by p16INK4a expression, is a defining feature of PD-1-expressing exhausted human T cells, and targeting p16INK4a improved the function of exhausted CAR T cells. Primary human T cells were stimulated weekly with anti-CD3/CD28 beads until growth stopped after 5 to 7 rounds, around days 35 to 49. Repeatedly stimulated CD8+ T cells showed a senescence gene signature, DNA damage, and SA-β-Gal activity restricted to PD-1+ cells, without critically short telomeres. Antigen-specific T cells stimulated repeatedly with an EBV epitope also showed SA-β-Gal induction in PD-1-expressing cells. A similar pattern appeared in mice with chronic LCMV clone 13 infection. Inhibiting p38MAPK…

Download Now →

Author: Valérie Janelle, Mathieu Neault +11 more

Publications CAR T Cells

Publication Date: August 3, 2021

Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy

Commercial CAR T cell production is moving from open, manual, academic-style processes toward closed and automated systems that can scale. Five autologous CAR T products were approved in the U.S. as of the review, all using viral vectors. Closed platforms reduce handling but are costly and make one product per instrument, so scaling out needs parallel units. Allogeneic products could instead be scaled up from one donor collection, though they face allo-rejection and shorter persistence. Nonviral and genome-editing delivery, shortened expansion (some protocols use only a few days) and slow sterility testing are discussed, along with GMP staffing, regulatory and decentralized manufacturing…

Download Now →

Author: Mohamed Abou-el-Enein, Magdi Elsallab +7 more

Publications VST Cells

Publication Date: August 1, 2021

BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study

In an open-label pilot study at the NIH Clinical Center, partially HLA-matched BK virus-specific T cells (PyVST) made from first-degree relatives were safely given to 12 adults with progressive multifocal leukoencephalopathy. Twenty-three clinical products were generated without manufacturing failure and 14 were infused, after 14-day expansion with a mean 7.6-fold increase. Patients received 1×10^6 T cells/kg, then up to two doses of 2×10^6 T cells/kg. Among 134 adverse events recorded, none of high grade was deemed treatment related, and no immune reconstitution inflammatory syndrome occurred. Seven patients survived PML for more than one year, whereas five died within three months. Base…

Download Now →

Author: Irene Cortese, Erin S Beck +23 more

Publications VST Cells G-Rex®24 Well Plate

Publication Date: July 27, 2021

Virus Induced Lymphocytes (VIL) as a novel viral antigen‑specific T cell therapy for COVID‑19 and potential future pandemics

Bead-based artificial antigen-presenting cells (VIPR particles) carrying a SARS-CoV-2 Spike peptide-MHC pentamer and anti-CD28 antibodies expanded virus-specific CD8+ T cells from convalescent COVID-19 donors more than 1000-fold on average within 7 days. T cells were cultured with one particle per 20 T cells in medium with 6000 IU/ml IL-2, IL-7, IL-15 and N-acetylcysteine, in G-Rex® 24-well plates. Cultures seeded with 1 × 10^6 T cells reached 2.6 to 4.5 × 10^7 cells by day 7, with an average of 2.4 × 10^5 SARS-CoV-2-specific CD8+ T cells per million T cells cultured. CMV-specific CD8+ T cells expanded on average more than 700-fold. Expanded virus-specific cells showed an effector memory…

Download Now →

Author: Rohan Sivapalan, Jinyan Liu +6 more

Publications NK Cells

Publication Date: July 23, 2021

CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines In Vitro

CAR-NK cells built from the S309 neutralizing-antibody scFv recognized and killed cells expressing the SARS-CoV-2 spike protein in vitro, including spike carrying D614G, E484K and N501Y changes. S309 CAR-expressing NK-92MI cells bound the receptor-binding domain and pseudotyped viral particles, with binding efficiency above 90%. They degranulated and lysed 293T-hACE2-RBD and A549-Spike targets in 4-hour chromium release assays, while irrelevant HepG2 targets showed no significant difference from parental NK-92MI cells. Primary NK cells expanded from blood reached about 90% purity and roughly 80% CAR transduction, and killed A549-Spike and A549-Spike D614G cells. S309 CAR-NK cells outperfo…

Download Now →

Author: Minh Tuyet Ma, Saiaditya Badeti +14 more

Publications CAR T Cells G-Rex®24 Well Plate

Publication Date: July 23, 2021

Spatio‑temporal biodistribution of 89Zr‑oxine labeled huLym‑1‑A‑BB3z‑CAR T‑cells by PET imaging in a preclinical tumor model

Serial PET/MRI tracking of 89Zr-oxine-labeled huLym-1-A-BB3z CAR T-cells in NSG mice bearing subcutaneous Raji lymphoma showed that intravenously infused cells first lodged in the lungs, then shifted to the liver and spleen, and reached the tumor only at low levels. Mice received low, middle or high doses (1.87, 7.14 or 16.83 × 10^6 cells) and were imaged 3, 24, 48 and 120 hours after injection. Tumor uptake on day 2 was significantly higher with the middle and high doses than with the low dose, and tumor-to-blood ratios in the middle-dose group indicated accumulation from day 1 through day 5. Labeling did not significantly change CAR T-cell viability, proliferation, cytotoxicity or IL-2…

Download Now →

Author: Naomi S. Sta Maria, Leslie A. Khawli +8 more

Publications Other G-Rex®6 Well Plate

Publication Date: July 16, 2021

Innovative therapeutic strategy for B- cell malignancies that combines obinutuzumab and cytokine- induced killer cells

Adding the bispecific antibody blinatumomab to cytokine-induced killer (CIK) cell cultures allowed patient-derived effector cells to expand while eliminating malignant B cells, and the resulting cells could be redirected against CD20-positive lymphoma by obinutuzumab. In nine patients with B-cell malignancies, 5 × 10^6 PBMCs yielded 59.3 × 10^6 cells with blinatumomab versus 11.2 × 10^6 with the standard protocol after two weeks, and CD19-positive and CD20-positive cells were eradicated by day 14. Healthy-donor CIK cells combined with obinutuzumab lysed seven B-cell lines and primary patient samples. In mice carrying a mantle cell lymphoma xenograft, only CIK plus obinutuzumab delayed tum…

Download Now →

Author: Anna Dalla Pietà, Elisa Cappuzzello +13 more

Publications NK Cells G-Rex®24 Well Plate

Publication Date: July 14, 2021

Differentiation of natural killer cells from induced pluripotent stem cells under defined, serum- and feeder-free conditions

Natural killer (NK) cells differentiated from induced pluripotent stem cells without feeder or stromal cells, serum or peripheral blood killed solid tumor cells at levels mostly comparable to or higher than blood-derived NK cells. Two lines were used: the centrally authenticated KOLF2 line and hiPSC01, reprogrammed by the authors. Spin embryoid bodies seeded at 3000 cells per well yielded predominantly CD34+ hematopoietic progenitors by day 11 (60.40% for hiPSC01, 57.03% for KOLF2). Four weeks of NK differentiation gave 31.68% (hiPSC01) and 17.06% (KOLF2) CD56+/CD3− cells, and two weeks of cytokine expansion raised purity above 70%. Expansion in a 24-well G-Rex® plate reached up to 80-fol…

Download Now →

Author: Kyle B. Lupo, Jung-Il Moon +2 more

Publications VST Cells G-Rex®10, G-Rex®100

Publication Date: July 14, 2021

Cytometric analysis of T cell phenotype using cytokine profiling for improved manufacturing of an EBV- specific T cell therapy

Moving a lymphoblastoid cell line-driven EBV-specific T cell process to G-Rex® flasks, GMP-grade xeno-free reagents and a reduced LCL dose gave a comparable or improved product, as judged by combined surface and intracellular cytokine flow cytometry. Across six donor lines, functional cytokine output peaked by the third or fourth stimulation round. In G-Rex®100 flasks the CD8-positive fraction reached 90.2% versus 78.4% in standard flasks. GMP-grade reagents improved retention of central memory cells. Reducing the stimulation ratio from 1 T cell:5 LCL to 1:1 gave comparable expansion (21.68-fold versus 28.1-fold) but higher IFN-γ cMFI (162.5 versus 77.65). t-SNE condensed the multiparamet…

Download Now →

Author: Rachel S Cooper, Aleksandra Kowalczuk +5 more

Publications CAR T Cells

Publication Date: June 24, 2021

Immune inactivation of anti-simian immunodeficiency virus chimeric antigen receptor T cells in rhesus macaques

Anti-SIV chimeric antigen receptor T cells that killed infected cells efficiently in vitro failed to expand or show antiviral activity after infusion into rhesus macaques, and host antibodies appear to explain the gap. CAR T cells built on the ITS06 (V1) and ITS52 (V3) antibodies were potent in culture, and the ITS06 vector added C46 for protection against SIV infection and CXCR5 for follicle homing. In two ART-suppressed macaques given 6.2 × 10^7 or 9 × 10^6 cells/kg, CAR T cells were detectable in blood only up to 7 days. One animal developed anti-scFv antibodies, and plasma from SIV-infected animals blocked killing by ITS06 and ITS52 CAR T cells, but not CD4CAR or VRC26 CAR T cells.

Download Now →

Author: Françoise Haeseleer, Yoshinori Fukazawa +12 more

Publications CD34 Cells, NK Cells, Other, T-Cells

Publication Date: June 23, 2021

AsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicines

AsCas12a Ultra, a double mutant (M537R/F870L) of AsCas12a selected by directed evolution in bacteria, raises editing in human cells to near-complete levels while keeping the specificity of the wild-type enzyme. Across 96 TTTN target sites in HEK293 cells, median editing at canonical TTTV sites reached 97% versus 33% for wild type. In primary T cells, 1 μM total RNP simultaneously disrupted TRAC, B2M and CIITA with 93 ± 2% indels, and AAV6-templated knock-in reached 57% and 56% at single loci. GUIDE-seq found no detectable off-target tag incorporation for three high-activity guides in T cells. In NK cells, TGFBR2 knockout and anti-EGFR CAR knock-in enhanced tumor spheroid killing in vitro.

Download Now →

Author: Liyang Zhang, John A. Zuris +22 more